ViiV Healthcare, a specialist HIV company, announced on Wednesday positive results from the PASO DOBLE Phase IV randomized clinical trial. This trial compared the 2-drug regimen DOVATO with the 3-drug regimen BIKTARVY for the treatment of HIV-1 over a 48-week period.
The open-label, randomized multicenter clinical trial successfully met its primary endpoint, with safety profiles similar through week 48. The company, which was established by GSK Plc. and Pfizer Inc., also noted that participants on the 2-drug regimen DOVATO experienced lower average weight gain compared to those on the 3-drug regimen BIKTARVY.
A total of 553 virally suppressed individuals living with HIV switched treatments during the PASO DOBLE clinical trial.
As of the latest trading session on the New York Stock Exchange, GSK's stock is priced at $38.79, reflecting a 2.46 percent decline, while Pfizer's stock is at $30.98, down by 1.32 percent.
